Abviris
Private Company
Funding information not available
Overview
Abviris, founded in 2018 and based in Berlin, is a private diagnostics company focused on transforming HPV-related cancer screening through serology. Its core technology enables the detection of specific antibody biomarkers from a simple blood draw, with its flagship product, Prevo-Check®, designed for early detection of precancerous lesions and monitoring after treatment. The company is pre-revenue and in the development/commercialization stage, having recently secured nearly €2 million in funding to expand its biomarker platform. Abviris represents a novel approach in a large, established screening market dominated by molecular and cytology tests.
Technology Platform
Proprietary HPV serology platform detecting antibody biomarkers from a blood sample to identify progressing precancerous lesions and monitor treatment response.
Opportunities
Risk Factors
Competitive Landscape
Abviris competes in the HPV diagnostics market dominated by large companies offering DNA-based tests (e.g., Roche cobas®, Qiagen Digene HC2, BD Onclarity). Its serology approach is differentiated but unproven at scale. It also faces competition from emerging multi-cancer early detection (MCED) blood tests, though these are typically focused on later-stage disease.